BriaCell Therapeutics Corp.BCTXNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank33
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P33
Within normal range
vs 5Y Ago
-0.4x
Contraction
Streak
4 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -15.36% |
| Q3 2025 | -8.72% |
| Q2 2025 | 1.03% |
| Q1 2025 | 5.43% |
| Q4 2024 | 12.16% |
| Q3 2024 | -15.87% |
| Q2 2024 | -0.41% |
| Q1 2024 | -4.00% |
| Q4 2023 | -34.77% |
| Q3 2023 | 37.14% |
| Q2 2023 | 27.60% |
| Q1 2023 | -31.99% |
| Q4 2022 | -2.77% |
| Q3 2022 | 25.10% |
| Q2 2022 | -4.53% |
| Q1 2022 | 38.98% |
| Q4 2021 | 41.16% |
| Q3 2021 | -73.04% |
| Q2 2021 | 18065.80% |
| Q1 2021 | -91.66% |
| Q4 2020 | 39.72% |
| Q3 2020 | -46.95% |
| Q2 2020 | -37.27% |
| Q1 2020 | 20.51% |
| Q4 2019 | 38.32% |
| Q3 2019 | -9.41% |
| Q2 2019 | 90.15% |
| Q1 2019 | -15.39% |
| Q4 2018 | -60.28% |
| Q3 2018 | -10.20% |
| Q2 2018 | 220.42% |
| Q1 2018 | 34.07% |
| Q4 2017 | -38.75% |
| Q3 2017 | -27.83% |
| Q2 2017 | 75.42% |
| Q1 2017 | 33.70% |
| Q4 2016 | 134.20% |
| Q3 2016 | -257.28% |
| Q2 2016 | -69.57% |
| Q1 2016 | 541.91% |